JP2020530298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530298A5 JP2020530298A5 JP2020507585A JP2020507585A JP2020530298A5 JP 2020530298 A5 JP2020530298 A5 JP 2020530298A5 JP 2020507585 A JP2020507585 A JP 2020507585A JP 2020507585 A JP2020507585 A JP 2020507585A JP 2020530298 A5 JP2020530298 A5 JP 2020530298A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- binding substance
- substance according
- cells
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 58
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 58
- 239000000126 substance Substances 0.000 claims description 58
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 42
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 20
- 239000011230 binding agent Substances 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000002865 immune cell Anatomy 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102220467431 Protein Jade-1_R35A_mutation Human genes 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 102220521895 THAP domain-containing protein 1_L32A_mutation Human genes 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000000220 brain stem cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000004252 chorionic villi Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 102220067601 rs150464212 Human genes 0.000 claims description 2
- 102220008221 rs199476324 Human genes 0.000 claims description 2
- 102220065721 rs750676165 Human genes 0.000 claims description 2
- 102200072502 rs869025313 Human genes 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000004435 urinary system cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 229940047122 interleukins Drugs 0.000 claims 2
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542921P | 2017-08-09 | 2017-08-09 | |
| US62/542,921 | 2017-08-09 | ||
| PCT/US2018/045743 WO2019032663A1 (en) | 2017-08-09 | 2018-08-08 | PD-1 AND PD-L1 BINDING AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530298A JP2020530298A (ja) | 2020-10-22 |
| JP2020530298A5 true JP2020530298A5 (https=) | 2021-09-16 |
| JP7423511B2 JP7423511B2 (ja) | 2024-01-29 |
Family
ID=65271869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507585A Active JP7423511B2 (ja) | 2017-08-09 | 2018-08-08 | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11498966B2 (https=) |
| EP (1) | EP3664829A4 (https=) |
| JP (1) | JP7423511B2 (https=) |
| CN (2) | CN119285770A (https=) |
| CA (1) | CA3069994A1 (https=) |
| WO (1) | WO2019032663A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| CN113286613A (zh) * | 2018-10-29 | 2021-08-20 | Umc乌得勒支控股有限公司 | IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤 |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| WO2020215020A1 (en) | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Humanized anti-pd-l1 antibodies |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN112142842B (zh) | 2019-06-27 | 2023-09-01 | 启愈生物技术(上海)有限公司 | 抗PD-L1纳米抗体及其Fc融合蛋白和应用 |
| EP4034146A4 (en) * | 2019-09-26 | 2024-03-06 | Orionis Biosciences, Inc. | CONJUGATED CHIMERIC PROTEINS |
| AU2020353660A1 (en) * | 2019-09-26 | 2022-04-14 | Orionis Biosciences, Inc. | PD-L1 targeted chimeric proteins and uses thereof |
| JP7738551B2 (ja) * | 2019-10-30 | 2025-09-12 | サンヨウ バイオファーマシューティカルズ カンパニー リミテッド | Ｐｄ－ｌ１結合分子 |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| AU2020402496A1 (en) * | 2019-12-11 | 2022-06-16 | WuXi Biologics Ireland Limited | Bi-functional antibody against PD-L1 and TGFβ |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| US20240287147A1 (en) * | 2020-11-30 | 2024-08-29 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| JP7773238B2 (ja) * | 2021-02-19 | 2025-11-19 | シャペロン インク． | Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途 |
| TWI833227B (zh) * | 2021-05-28 | 2024-02-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向pd-l1和cd73的特異性結合蛋白及其應用 |
| CN118201953A (zh) * | 2021-08-18 | 2024-06-14 | 瑞美德生物医药科技有限公司 | 新型干扰素变体及其双功能融合分子 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CA3251753A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | PRE-TARGETTING |
| CN117736323A (zh) * | 2022-09-21 | 2024-03-22 | 三优生物医药(上海)有限公司 | 抗pd-l1抗体及其用途 |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| CN120603849A (zh) * | 2023-01-18 | 2025-09-05 | 科望(苏州)生物医药科技有限公司 | 抗pdl1单域抗体、融合蛋白及其用途 |
| WO2025217579A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Anti-hsa vhh antibodies and compositions thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2026015864A1 (en) * | 2024-07-12 | 2026-01-15 | Outpace Bio, Inc. | Cd8 binding polypeptides and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2055445T3 (es) | 1989-08-22 | 1994-08-16 | Immunex Corp | Proteinas de fusion que comprenden gm-csf e il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| CN102892786B (zh) * | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| HRP20201595T1 (hr) * | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN104245734B (zh) | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| ES2800426T3 (es) | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| WO2015007536A2 (en) | 2013-07-18 | 2015-01-22 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
| JP6595988B2 (ja) | 2013-07-19 | 2019-10-23 | ヴィブ ブイゼットダブリュー | ターゲットされる修飾ｔｎｆファミリーメンバー |
| DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
| CA2918119C (en) | 2013-07-19 | 2022-11-29 | Centre Hospitalier Regional Universitaire De Montpellier | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
| BR112016002614B8 (pt) | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Imunocitoquina e composição farmacêutica |
| MX375378B (es) * | 2013-09-27 | 2025-03-06 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1. |
| EA201691376A1 (ru) * | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016197367A1 (en) * | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CA3040802A1 (en) * | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3580230B1 (en) | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
-
2018
- 2018-08-08 JP JP2020507585A patent/JP7423511B2/ja active Active
- 2018-08-08 US US16/636,501 patent/US11498966B2/en active Active
- 2018-08-08 CA CA3069994A patent/CA3069994A1/en active Pending
- 2018-08-08 CN CN202411067631.5A patent/CN119285770A/zh active Pending
- 2018-08-08 WO PCT/US2018/045743 patent/WO2019032663A1/en not_active Ceased
- 2018-08-08 CN CN201880065727.4A patent/CN111328286B/zh active Active
- 2018-08-08 EP EP18844220.6A patent/EP3664829A4/en active Pending
-
2022
- 2022-10-05 US US17/938,109 patent/US12351633B2/en active Active
-
2025
- 2025-06-03 US US19/226,780 patent/US20250361305A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530298A5 (https=) | ||
| JP7574348B2 (ja) | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 | |
| CN104403004B (zh) | 抗体‑干扰素异二聚体的制备和用途 | |
| JP7296367B2 (ja) | 二重特異性組換えタンパク質およびその応用 | |
| JP2020506727A5 (https=) | ||
| JP2020530302A5 (https=) | ||
| JP2020530299A5 (https=) | ||
| JP2020508329A5 (https=) | ||
| JP2020505955A5 (https=) | ||
| JP7677908B2 (ja) | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 | |
| JP2023089171A (ja) | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 | |
| JP2022101631A (ja) | 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合 | |
| US20160235842A1 (en) | Medical uses of cd38 agonists | |
| JP2017031215A (ja) | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す | |
| CN114181960A (zh) | 嵌合抗原受体和使用方法 | |
| JP2021524276A5 (https=) | ||
| JP2015521607A (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2019534710A5 (https=) | ||
| JP2022512541A5 (https=) | ||
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| JP2022512539A5 (https=) | ||
| JP2021500320A (ja) | 癌の治療のための配合剤 | |
| WO2014166029A1 (zh) | 针对表皮生长因子受体的抗体 | |
| JP2022503621A5 (https=) |